Literature DB >> 6235569

Factors influencing immune complex localisation.

L Schrieber, R Penny.   

Abstract

In systemic immune complex (IC) diseases such as SLE and rheumatoid vasculitis, IC accumulate in a number of tissues, either after deposition from the circulation or from in situ formation. The tissue localisation of IC depends on a delicate balance between the production of IC and the ability of the mononuclear phagocytic system (MPS) to remove them from blood. At times IC are cleared inefficiently, persist in the circulation and subsequently localise in tissues. This review evaluates the role of local tissue factors - anatomical, physiological, physical and immunological - in this process. We report on our studies examining the significance of C3b and IgG Fc receptors in tissues subject to IC deposition. No evidence for such receptors was found with the exception of a C3b receptor in human glomeruli. Our negative findings may be due to methodological difficulties in the identification of in situ receptors. Alternatively, immune receptors may not be present at these extra-glomerular sites and would therefore be unlikely to participate in IC localisation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6235569     DOI: 10.1007/bf00541177

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  142 in total

1.  Experimental anaphylactic lesions of the coronary arteries of the sclerotic type, commonly associated with rheumatic fever and disseminated lupus erythematosus.

Authors:  A R RICH; J E GREGORY
Journal:  Bull Johns Hopkins Hosp       Date:  1947-11

Review 2.  The vascular endothelium-pathobiologic significance.

Authors:  G Thorgeirsson; A L Robertson
Journal:  Am J Pathol       Date:  1978-12       Impact factor: 4.307

Review 3.  Circulating immune complexes (CIC) in connective tissue diseases (CTD).

Authors:  L Schrieber; R N Maini
Journal:  Neth J Med       Date:  1984       Impact factor: 1.422

4.  Receptors on human synovial cells.

Authors:  L Schrieber; R Penny
Journal:  Arthritis Rheum       Date:  1980-11

5.  Immunopathologic studies of pneumonitis in systemic lupus erythematosus.

Authors:  T Inoue; Y Kanayama; A Ohe; N Kato; T Horiguchi; M Ishii; K Shiota
Journal:  Ann Intern Med       Date:  1979-07       Impact factor: 25.391

6.  The role of immune complexes in the pathogenesis of disease.

Authors:  B S Andrews; R Penny
Journal:  Aust N Z J Med       Date:  1976-12

7.  In vitro demonstration of a particular affinity of glomerular basement membrane and collagen for DNA. A possible basis for a local formation of DNA-anti-DNA complexes in systemic lupus erythematosus.

Authors:  S Izui; P H Lambert; P A Miescher
Journal:  J Exp Med       Date:  1976-08-01       Impact factor: 14.307

8.  The localization of circulating immune complexes in experimental serum sickness. The role of vasoactive amines and hydrodynamic forces.

Authors:  W T Kniker; C G Cochrane
Journal:  J Exp Med       Date:  1968-01-01       Impact factor: 14.307

9.  A receptor for the third component of complement in the human renal glomerulus.

Authors:  M C Gelfand; M M Frank; I Green
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

10.  Experimental immune complex disease of the lung. The pathogenesis of a laboratory model resembling certain human interstitial lung diseases.

Authors:  J R Brentjens; D W O'Connell; I B Pawlowski; K C Hsu; G A Andres
Journal:  J Exp Med       Date:  1974-07-01       Impact factor: 14.307

View more
  2 in total

1.  Prospective study of familial canine dermatomyositis. Correlation of the severity of dermatomyositis and circulating immune complex levels.

Authors:  A M Hargis; D J Prieur; K H Haupt; T L McDonald; M P Moore
Journal:  Am J Pathol       Date:  1986-06       Impact factor: 4.307

2.  Borderline-tissues as sites of antigen deposition and persistence--a unifying concept of rheumatoid inflammation?

Authors:  L C Schulz; U Schaening; M Peña; W Hermanns
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.